Findings

What do systematic reviews say?

4,919 questions · 13,869 findings · 2,177 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Lysine hyaluronate vs sodium hyaluronate

Adverse events ‐ not reported · people with pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Dressings and topical agents containing hyaluronic acid for chronic wound healing 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Iridotomy vs no iridotomy

Glaucoma progression at 12 months, measured by additional visual field defects · people with primary angle‐closure suspect

The review found no eligible studies for this question.

1 finding from 1 review

Iridotomy to slow progression of visual field loss in angle‐closure glaucoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Iridotomy vs no iridotomy

Mean number of antiglaucoma medications at 1‐year · people with primary angle‐closure suspect

The review found no eligible studies for this question.

1 finding from 1 review

Iridotomy to slow progression of visual field loss in angle‐closure glaucoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Iridotomy vs no iridotomy

Quality of life measures · people with primary angle‐closure suspect

The review found no eligible studies for this question.

1 finding from 1 review

Iridotomy to slow progression of visual field loss in angle‐closure glaucoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFX film‐coated tablet vs DFX dispersible tablet

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs deferoxamine

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs deferoxamine

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs deferoxamine

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP and DFX

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

Adherence to iron chelation therapy (%, SD)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

SAEs

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medication management vs usual care

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found